Cidara Therapeutics Shares Are Trading Higher After the Company Announced the Divestiture of Rezafungin to Mundipharma, Reacquired Global Development and Commercial Rights to CD388 and Announced $240 Million in Private Placement Financing.
Cidara Therapeutics Shares Are Trading Higher After the Company Announced the Divestiture of Rezafungin to Mundipharma, Reacquired Global Development and Commercial Rights to CD388 and Announced $240 Million in Private Placement Financing.
Cidara Therapeutics宣布将Rezafungin剥离给Mundipharma，重新收购了 CD388 的全球开发和商业权，并宣布了2.4亿美元的私募融资，此后，该公司股价走高。
Cidara Therapeutics Shares Are Trading Higher After the Company Announced the Divestiture of Rezafungin to Mundipharma, Reacquired Global Development and Commercial Rights to CD388 and Announced $240 Million in Private Placement Financing.
Cidara Therapeutics宣布将Rezafungin剥离给Mundipharma，重新收购了 CD388 的全球开发和商业权，并宣布了2.4亿美元的私募融资，此后，该公司股价走高。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。